1-9 of 9
Dyana T. Saenz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1071: Targeted therapy evaluation in novel pre-clinical in vitro and in vivo models of Richter transformation

Warren C. Fiskus, Abhishek Maiti, Dyana T. Saenz, Christopher P. Mill, Joseph D. Khoury, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1071.
https://doi.org/10.1158/1538-7445.AM2019-1071
Published: 01 July 2019
View article titled, Abstract 1071: Targeted therapy evaluation in novel pre-clinical <em>in vitro</em> and <em>in vivo</em> models of Richter transformation
Journal Articles

Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor

Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Christopher P. Mill, Steve Horrigan, Raffaella Soldi, Joseph D. Khoury, Sunil Sharma, Srdan Verstovesek, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3036.
https://doi.org/10.1158/1538-7445.AM2019-3036
Published: 01 July 2019
View article titled, Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor
Journal Articles

Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML

Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Christopher P. Mill, Joseph D. Khoury, Srdan Verstovsek, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3836.
https://doi.org/10.1158/1538-7445.AM2019-3836
Published: 01 July 2019
View article titled, Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML
Journal Articles

Abstract 802: Targeted inhibition of KDM1A and BET proteins or DNMT1 exerts synergistic lethal activity against human AML blast progenitor cells

Warren C. Fiskus, Christopher P. Mill, Dyana T. Saenz, Agnieszka J. Nowak, Baohua Sun, David N. Saenz, Steven M. Kornblau, Sunil Sharma, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 802.
https://doi.org/10.1158/1538-7445.AM2018-802
Published: 01 July 2018
View article titled, Abstract 802: Targeted inhibition of KDM1A and BET proteins or DNMT1 exerts synergistic lethal activity against human AML blast progenitor cells
Journal Articles

Abstract 3884: Novel RUNX1 targeted therapy for AML expressing mutant RUNX1

Christopher P. Mill, Courtney D. DiNardo, Warren Fiskus, Dyana T. Saenz, Agnieszka J. Nowak, Baohua Sun, David N. Saenz, Steven M. Kornblau, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3884.
https://doi.org/10.1158/1538-7445.AM2018-3884
Published: 01 July 2018
View article titled, Abstract 3884: Novel RUNX1 targeted therapy for AML expressing mutant RUNX1
Journal Articles

Abstract LB-081: Novel and effective RUNX1-targeted therapy for AML expressing RUNX1 mutation

Christopher P. Mill, Courtney DiNardo, Warren C. Fiskus, Dyana T. Saenz, Baohua Sun, Agnieszka J. Nowak, Misun Kim, Mark Routbort, Koichi Takahashi, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): LB-081.
https://doi.org/10.1158/1538-7445.AM2017-LB-081
Published: 01 July 2017
View article titled, Abstract LB-081: Novel and effective RUNX1-targeted therapy for AML expressing RUNX1 mutation
Journal Articles

Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Dyana T. Saenz, Warren C. Fiskus, Kanak Raina, Taghi Manshouri, Kevin G. Coleman, Yimin Qian, Andrew P. Crew, Angela Shen, Christopher P. Mill, Baohua Sun, Misun Kim, Agnieszka J. Nowak, Srdan Verstovsek, Craig M. Crews, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5067.
https://doi.org/10.1158/1538-7445.AM2017-5067
Published: 01 July 2017
View article titled, Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
Journal Articles

SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents

Warren Fiskus, Veena Coothankandaswamy, Jianguang Chen, Hongwei Ma, Kyungsoo Ha, Dyana T. Saenz, Stephanie S. Krieger, Christopher P. Mill, Baohua Sun, Peng Huang, Jeffrey S. Mumm, Ari M. Melnick, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2016) 76 (18): 5467–5478.
https://doi.org/10.1158/0008-5472.CAN-16-0126
Published: 15 September 2016
View article titled, SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents
Open the PDF for SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents in another window
Includes: Supplementary data
Journal Articles

Abstract 4699: Superior lethal activity of single agent BET protein PROTAC compared to bromodomain inhibitor or in combination with JAK inhibitor against post-myelofibrosis secondary AML cells

Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Jing Lu, Yimin Qian, Kanak Raina, Baohua Sun, Stephanie S. Krieger, Simrit Parmar, Srdan Verstovsek, Kapil N. Bhalla
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4699.
https://doi.org/10.1158/1538-7445.AM2016-4699
Published: 15 July 2016
View article titled, Abstract 4699: Superior lethal activity of single agent BET protein PROTAC compared to bromodomain inhibitor or in combination with JAK inhibitor against post-myelofibrosis secondary AML cells